Effect of intratesticular administration of BCG on testicular function
- 20 Downloads
- 2 Citations
Abstract
Four patients suffering from carcinoma of the prostate (2 in stage C and 2 in stage D) in whom orchidectomy was indicated clinically, were enrolled in the study. Two patients were given a single injection of 25 units of BCG per testis and the other two received 50 units intratesticularly. Testicular biopsy at 0, 4 and 16 weeks showed the effects of the procedure in the tubular and interstitial compartment. The tubules were partially or completely atrophied, Sertoli cells were vacuolated. In the interstitium, mononuclear infiltration was evident. The reaction was more intense in patients receiving 50 units. The plasma testosterone after a slight drop in the first month returned to normal and pretreatment levels, respectively, and remained so during the eight months of observation. There was no significant change either in plasma oestradiol and prolactin or in T3, T4 and cortisol levels. FSH and LH, however, increased beyond the basal levels after an initial drop. The general condition of the patients remained good. All four patients gained weight. No side effects other than scrotal swelling during the first few weeks were either seen or reported by the patients. The swelling subsided after four weeks.
This preliminary study indicates that there is a partial or total destruction of geminal elements. As the plasma testosterone levels remained undiminished in these four cases over a period of 8 months, it is apparent that testosterone production is not affected by intratesticularly administered BCG.
Keywords
Cortisol Testosterone Oestradiol Prolactin Cortisol LevelPreview
Unable to display preview. Download preview PDF.
References
- 1.Alvarez, S. F., Faundes, A., Brache, V., Leon, P.: Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate.Contraception, 15, 635 (1977).PubMedGoogle Scholar
- 2.Alvarez, S. F., Brache, V., Leon, P., Faundes, A.: Inhibition of spermatogenesis with monthly injections of medroxyprogesterone acetate and low dose testosterone ananthate.Int. J. Androl., 2, 136 (1979).Google Scholar
- 3.Barfield, A., Melo, J. F., Coutinho, E., Alvarez, S. F., Faundes, A., Brache, V., Leon, P., Frick, J., Brenner, P. F., Mishell, D., Ortiz, A.: Pregnancies occurring at sperm concentrations below 10 million/ml during clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.Contraception, 20, 121 (1979).PubMedGoogle Scholar
- 4.Bartke, A., Steele, R. E., Musti, N., Caldwell, B. V.: Fluctuations in plasma testosterone levels in adult male rats and mice.Endocrinology, 92, 1123 (1973).Google Scholar
- 5.Brenner, P. F., Bernstein, G. S., Roy, S., Jecht, E. E., Mishell, D. R. Jr.: Administration of norethandrolone and testosterone as a contraceptive agent for men.Contraception, 11, 207 (1977).Google Scholar
- 6.Brenner, P. F., Mishell, D. R., Jr., Bernstein, G. S., Ortiz, A.: Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive.Contraception, 15, 679 (1977).PubMedGoogle Scholar
- 7.Coutinho, E. M., Melo, J. F.: Successful inhibition of spermatogenesis in man without loss of libido: a potential new approach to male contraception.Contraception, 8, 207 (1973).Google Scholar
- 8.Crosignani, P. G., Nakamura, R. M., Hovland, D. N., Mishell, D. R. Jr.: A method of solid phase radioimmunoassay utilizing polypropylene discs.J. Clin. Endocrinol. Metab., 30, 153 (1970).Google Scholar
- 9.Frick, J.: Control of spermatogenesis in men by combined administration of progestin and androgen.Contraception, 8, 191 (1973).Google Scholar
- 10.Frick, J., Bartsch, G., Weiske, W. H.: The effect of monthly depot medroxyprogesterone acetate and testosterone enanthate on human spermatogenesis. I. Uniform dosage levels.Contraception, 15, 649 (1977).PubMedGoogle Scholar
- 11.Frick, J.: Hormone determinations in andrology.Andrologia, 12, 211 (1980).PubMedGoogle Scholar
- 12.Hotchkiss, J., Atkinson, L. E., Knobil, E.: Time course of serum estrogen and luteinizing hormone concentrations during the menstrual cycle of the rhesus monkey.Endocrinology, 89, 177 (1971).PubMedGoogle Scholar
- 13.Mac Leod, J., Gold, R. Z.: The male factor in fertility and infertility. II. Spermatozoon counts in 1000 men of known fertility and in 1000 cases of infertile marriage.J. Urol., 66, 436 (1951).PubMedGoogle Scholar
- 14.Martinez-Pineiro, J. A., Muntanola, P.: Nonspecific immunotherapy with BCG vaccine in bladder tumors.Eur. Urol., 3, 11 (1977).PubMedGoogle Scholar
- 15.Melo, J. F., Coutinho, E. M.: Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate.Contraception, 15, 627 (1977).PubMedGoogle Scholar
- 16.Rehan, N. E., Sobrero, A. J., Fertig, J. W.: The semen of fertile men: statistical analyses of 1300 men.Fertil. Steril., 26, 492 (1975).PubMedGoogle Scholar
- 17.Talwar, G. P., Naz, R. K., Das, C., Das, R. P.: A practicable immunological approach to block spermatogenesis without loss of androgens.Proc. Natl. Acad. Sci. USA, 76, 10 (1979).Google Scholar
- 18.Torgersen, H.: Untersuchungen über die Verwendung von Bacterium Calmette-Guérin (BCG) als Spermatogenese-Hemmer bei Ratten und Kaninchen. Dissertation zur Erlangung des Doktorgrades an der Naturwissenschaftlichen Fakultät der Universität Salzburg, Austria 1980.Google Scholar
- 19.Van Zyl, J. A., Menkveld, R., Kotze, T. J., Retief, A. E., Van Niekerk, W. A.: Oligozoospermiate: A seven-year survey of the incidence, chromosomal aberrations, treatment and pregnancy rate.Int. J. Fertil., 20, 129 (1975).PubMedGoogle Scholar